TuHURA Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
HURA Nasdaq 2836 www.tuhurabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TuHURA Biosciences, Inc.

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers - Sep 14th, 2026 5:45 am
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Sep 8th, 2026 5:45 am
HURA: Milestone Progression Over Next 12 Months - Aug 26th, 2026 3:12 am
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - Aug 14th, 2026 9:05 am
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Aug 14th, 2026 5:45 am
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference - Jul 22nd, 2026 5:40 am
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - Jun 15th, 2026 5:45 am
HURA: Refining TBS-2025 Development Plan - May 26th, 2026 9:22 am
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - May 15th, 2026 3:00 pm
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - May 12th, 2026 5:30 am
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - Apr 22nd, 2026 5:30 am
Is TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money? - Apr 20th, 2026 8:14 am
HURA: 2025 Financial Results - Apr 9th, 2026 5:32 am
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - Apr 7th, 2026 5:45 am
TuHURA Biosciences, Inc.'s (NASDAQ:HURA) Shift From Loss To Profit - Apr 2nd, 2026 4:13 am
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - Apr 1st, 2026 5:45 am
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - Mar 23rd, 2026 5:45 am
TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers - Feb 17th, 2026 5:45 am